Autonomic and Renal Contributions to Hypertension With ADT
Virginia Commonwealth University · with National Heart, Lung, and Blood Institute (NHLBI) · NCT07848828
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 40+ · Men only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 4
- Target enrollment
- 50
- US sites recruiting
- 1
- Study start
- August 1, 2026
- Record last updated
- September 30, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.
Being studied: Gonadotropin Releasing Hormone Agonists (GNRH); Androgen receptor (AR) inhibitor; Placebo
Conditions: Androgen Deprivation Therapy; Prostate Cancer; Hypertension; Autonomic Dysfunction; Renal Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- age 40+ years;
- resting blood pressure \<140/90 mmHg;
- fasted blood glucose \<126 mg/dL;
- testosterone ≥400 ng/dL;
- sedentary to recreationally active;
- nonsmokers;
- healthy as determined by medical history, physical exam, blood and urine chemistries and resting and exercise ECG during a physician supervised graded exercise treadmill test OR recent diagnosis of non-metastatic prostate cancer with plans to undergo androgen deprivation therapy;
- PSA \<4.00 ng/dL if in the non-cancer group;
- Gleason Score ≤7 if in the prostate cancer group;
- no use of medications that might influence cardiovascular function (e.g., antihypertensives, lipid-lowering medications);
- willing and able to be on GnRHagonist and AR inhibitor;
- not taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications, or willing to stop use for four weeks prior to the start of the study;
- not using exogenous sex hormones for at least one year
Exclusion Criteria
- -acute liver disease;
- chronic kidney disease, serum creatinine >1.3 mg/dL, macroalbuminuria >300 mg/g of proteinuria
- pre-existing or active cardiac, renal or hepatic disease, epilepsy or other seizure disorder;
- diabetes, active or chronic infection, disease that affects the nervous system;
- Gleason Score ≥8;
- thyroid dysfunction, defined as ultrasensitive TSH \<0.5 or >5.0 mU/L, volunteers with abnormal TSH values will be re-considered for participation after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement;
- tobacco use within the previous 12 months
Recruiting US locations
Virginia Commonwealth University
Richmond, VA 23220
Site contact: Matthew Babcock, PhD · (804) 396-4718 · babcockmc@vcu.edu
Study contacts (from the official record)
- Matthew Babcock, PhD · (804) 396-4718 · babcockmc@vcu.edu
Similar studies in Virginia
All heart & blood pressure studies in Virginia →- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Richmond, VA + 18 other US sites
- Eligibility basics
- Ages 18–100
- Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
- Location
- Richmond, VA + 64 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Merck Sharp & Dohme LLC
- Location
- Manassas, VA + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
- Location
- Falls Church, VA + 58 other US sites
- Eligibility basics
- Ages 18+